Those magic bullets that save thousands of lives each year – antibiotics – aren’t as resilient or effective as they once were, thanks to resistant bacteria.
Many drug makers are investing in new science and hope to develop new therapeutics that address autoimmune disease. BioSpace has captured some key efforts.
Many drug makers are investing in new science and hope to transition pain therapy approaches away from synthetic opioids. Biospace has tracked a few key alternative therapeutic candidates.
Biospace recently analyzed key emerging cell and gene therapy companies to get a handle on how this evolving science is beginning to make its way from research into clinical applications.
As countries reopen businesses and move toward normalcy, emerging biotech companies in the U.S. and Europe have encountered a mixed bag of experiences.
